Xi'an Key Laboratory of Digital Medical Technology of Ophthalmologic Imaging, Shaanxi Eye Hospital, Xi'an People's Hospital (Xi'an Fourth Hospital), Xi'an, 710004, Shaanxi, China.
Department of Pharmaceutical Chemistry & Analysis Pharmacy, Air Force Medical University, Xi'an, 710032, Shaanxi Province, China.
Nanomedicine (Lond). 2024;19(26):2171-2185. doi: 10.1080/17435889.2024.2393075. Epub 2024 Sep 3.
To assess mesenchymal stem cells (MSCs) as carriers for siRNA-loaded nanoparticles (NPs) for targeted therapy of experimental choroidal neovascularization (CNV). A poly (lactic-co-glycolic acid) (PLGA)-core/lipid-shell hybrid NP was designed. The transfection efficacy of MSCs with the hybrid NPs was assessed. Mice were intravenously injected with MSCs after laser photocoagulation and CNV was assessed at 7 days post-injection. The transfection efficiency of hybrid NPs into MSCs was 72.7%. mRNA expression in 661w cells co-cultured with MSC-hybrid-siRNA NPs was significantly lower. Intravenous delivery of MSC-hybrid-siRNA NPs greatly reduced CNV area and length. Intravenous injection of MSC-hybrid-siRNA NPs achieved therapeutic efficacy in reducing CNV area. The MSC-mediated homing enabled targeted inhibition of ocular angiogenesis.
为评估间充质干细胞(MSCs)作为载体制备负载 siRNA 的纳米颗粒(NPs),用于脉络膜新生血管(CNV)的靶向治疗。设计了一种聚(乳酸-共-乙醇酸)(PLGA)-核/脂质壳杂交 NP。评估了杂交 NPs 对 MSCs 的转染效率。激光光凝后,经静脉内注射 MSCs,注射后 7 天评估 CNV。杂交 NPs 转染 MSCs 的效率为 72.7%。与 MSC-杂交-siRNA NPs 共培养的 661w 细胞中 mRNA 表达显著降低。MSC-杂交-siRNA NPs 的静脉递送大大减少了 CNV 面积和长度。静脉注射 MSC-杂交-siRNA NPs 可实现减少 CNV 面积的治疗效果。MSC 介导的归巢使眼血管生成的靶向抑制成为可能。
Stem Cell Res Ther. 2018-10-25
Stem Cell Res Ther. 2024-10-10
Invest New Drugs. 2023-4
Int J Mol Sci. 2022-2-12
Pharmaceutics. 2021-11-8
Nat Commun. 2021-8-26